دورية أكاديمية
Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
| العنوان: | Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. |
|---|---|
| المؤلفون: | Lepage L; Department of Pharmacy and., Dufour AC; Department of Pharmacy and., Doiron J; Department of Pharmacy and., Handfield K; Department of Pharmacy and., Desforges K; Department of Pharmacy and., Bell R; Department of Pharmacy and., Vallée M; Division of Nephrology, Maisonneuve-Rosemont Hospital, Montreal, Canada; Department of Medicine., Savoie M; Department of Pharmacy and., Perreault S; Faculty of Pharmacy, and., Laurin LP; Division of Nephrology, Maisonneuve-Rosemont Hospital, Montreal, Canada; Department of Medicine., Pichette V; Division of Nephrology, Maisonneuve-Rosemont Hospital, Montreal, Canada; Department of Medicine, Maisonneuve-Rosemont Hospital Research Center, Montreal, Canada Department of Pharmacology, University of Montreal, Montreal, Canada; and., Lafrance JP; Division of Nephrology, Maisonneuve-Rosemont Hospital, Montreal, Canada; Maisonneuve-Rosemont Hospital Research Center, Montreal, Canada Department of Pharmacology, University of Montreal, Montreal, Canada; and jean-philippe.lafrance@umontreal.ca. |
| المصدر: | Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2015 Dec 07; Vol. 10 (12), pp. 2136-42. Date of Electronic Publication: 2015 Nov 17. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101271570 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-905X (Electronic) Linking ISSN: 15559041 NLM ISO Abbreviation: Clin J Am Soc Nephrol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Hagerstown, MD : Wolters Kluwer Health Original Publication: Washington, D.C. : American Society of Nephrology, c2005- |
| مواضيع طبية MeSH: | Hyperkalemia/*drug therapy , Polystyrenes/*therapeutic use , Potassium/*blood , Renal Insufficiency, Chronic/*complications, Aged ; Aged, 80 and over ; Biomarkers/blood ; Double-Blind Method ; Down-Regulation ; Female ; Humans ; Hyperkalemia/blood ; Hyperkalemia/diagnosis ; Hyperkalemia/etiology ; Male ; Middle Aged ; Polystyrenes/adverse effects ; Quebec ; Renal Insufficiency, Chronic/diagnosis ; Time Factors ; Treatment Outcome |
| مستخلص: | Background and Objectives: Hyperkalemia affects up to 10% of patients with CKD. Sodium polystyrene sulfonate has long been prescribed for this condition, although evidence is lacking on its efficacy for the treatment of mild hyperkalemia over several days. This study aimed to evaluate the efficacy of sodium polystyrene sulfonate in the treatment of mild hyperkalemia. Design, Setting, Participants, & Measurements: In total, 33 outpatients with CKD and mild hyperkalemia (5.0-5.9 mEq/L) in a single teaching hospital were included in this double-blind randomized clinical trial. We randomly assigned these patients to receive either placebo or sodium polystyrene sulfonate of 30 g orally one time per day for 7 days. The primary outcome was the comparison between study groups of the mean difference of serum potassium levels between the day after the last dose of treatment and baseline. Results: The mean duration of treatment was 6.9 days. Sodium polystyrene sulfonate was superior to placebo in the reduction of serum potassium levels (mean difference between groups, -1.04 mEq/L; 95% confidence interval, -1.37 to -0.71). A higher proportion of patients in the sodium polystyrene sulfonate group attained normokalemia at the end of their treatment compared with those in the placebo group, but the difference did not reach statistical significance (73% versus 38%; P=0.07). There was a trend toward higher rates of electrolytic disturbances and an increase in gastrointestinal side effects in the group receiving sodium polystyrene sulfonate. Conclusions: Sodium polystyrene sulfonate was superior to placebo in reducing serum potassium over 7 days in patients with mild hyperkalemia and CKD. (Copyright © 2015 by the American Society of Nephrology.) |
| References: | Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290. (PMID: 15114537) J Intensive Care Med. 2005 Sep-Oct;20(5):272-90. (PMID: 16145218) Resuscitation. 2006 Jul;70(1):10-25. (PMID: 16600469) Ann Intern Med. 2006 Aug 15;145(4):247-54. (PMID: 16908915) Arch Intern Med. 2009 Jun 22;169(12):1156-62. (PMID: 19546417) J Am Soc Nephrol. 2010 May;21(5):733-5. (PMID: 20167700) Clin Cardiol. 2012 Jan;35(1):32-6. (PMID: 22057933) Nephron Clin Pract. 2012;120(1):c8-16. (PMID: 22156587) Clin J Am Soc Nephrol. 2012 Aug;7(8):1234-41. (PMID: 22595825) CMAJ. 2013 Jun 11;185(9):E417-23. (PMID: 23649413) Am J Med Sci. 2014 Feb;347(2):93-100. (PMID: 23255245) Nat Rev Nephrol. 2014 Nov;10(11):653-62. (PMID: 25223988) JAMA. 2014 Dec 3;312(21):2223-33. (PMID: 25402495) N Engl J Med. 2015 Jan 15;372(3):211-21. (PMID: 25415805) N Engl J Med. 2015 Jan 15;372(3):222-31. (PMID: 25415807) |
| فهرسة مساهمة: | Keywords: double-blind method; humans; hyperkalemia; kidney failure, chronic; outpatients; polystyrene sulfonic acid; polystyrenes; potassium; randomized controlled trial; renal insufficiency, chronic |
| المشرفين على المادة: | 0 (Biomarkers) 0 (Polystyrenes) 70KO0R01RY (polystyrene sulfonic acid) RWP5GA015D (Potassium) |
| تواريخ الأحداث: | Date Created: 20151119 Date Completed: 20160913 Latest Revision: 20220408 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC4670766 |
| DOI: | 10.2215/CJN.03640415 |
| PMID: | 26576619 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1555-905X |
|---|---|
| DOI: | 10.2215/CJN.03640415 |